Novo Nordisk Shares Jump 3% as UK Approves Wegovy Pill
NVO•UK’s MHRA approved Novo Nordisk’s daily Wegovy GLP-1 semaglutide pill, making the UK the first European market to license the oral variant after the US and UAE, with prescriptions available within weeks. Novo Nordisk shares jumped 3% on the approval, eclipsing concerns over a recent IT security breach.
1. UK Approval of Wegovy Pill
The MHRA has authorized Novo Nordisk’s daily oral semaglutide pill, making the UK the first European market—after the US and UAE—to approve Wegovy in pill form. The pills, offering a daily alternative to weekly injections for adults with obesity or overweight plus a weight-related condition, will be available via private prescription within weeks.
2. Market Reaction and Stock Movement
Novo Nordisk shares rose 3% on the news of UK approval, reflecting investor confidence in expanded market access and expected revenue growth in Europe. The stock gain underscored the high market anticipation for oral GLP-1 treatments as obesity care demand surges.
3. Security Breach Overshadowed
Investor focus on the approval outpaced concerns about a recent IT security breach involving unauthorized system access. The incident did not disrupt production or regulatory submissions, limiting its impact on operations and investor sentiment.
4. Broader Implications for Obesity Care and Consumer Spending
With 15 million UK adults living with obesity and an estimated 1.9 million already using GLP-1 therapies, early research shows households on these drugs cut grocery spending by £780m in one year. This consumer shift highlights broader market opportunities and challenges for food and beverage brands as obesity treatments reshape purchasing patterns.
